Skip to main content

Table 4 Association between MMP9 overexpression and survival in patients with breast cancer

From: Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

Survival Subgroup No. of studies No. of patients I2 (%) P for heterogeneity Pooled HR (95%CI) P for effect size
DFS Overall 6 1002 70.5 0.005 1.73 (0.99–3.01) 0.052
Analysis model       
Univariate 6 1002 74.4 0.002 1.86 (1.05–3.31) 0.034
Multivariate 3 573 56.7 0.100 2.73 (1.33–5.61) 0.006
OS Overall 18 2687 24.7 0.164 1.52 (1.30–1.77) < 0.001
Ethnicity       
Caucasians 6 744 22.0 0.268 1.21 (0.81–1.80) 0.344
Asians 12 1943 25.0 0.198 1.58 (1.34–1.86) < 0.001
IHC analysis standard      
Percentage 7 1178 2.8 0.404 1.85 (1.32–2.59) < 0.001
SI 9 1239 24.4 0.226 1.51 (1.26–1.80) < 0.001
Other cut-offs 2 270 0 0.703 0.72 (0.36–1.45) 0.359
HR data       
Reported 14 2249 9.9 0.344 1.43 (1.21–1.67) < 0.001
Estimated 4 438 0 0.644 2.84 (1.71–4.73) < 0.001
Analysis model       
Univariate 14 2190 63.8 0.001 1.79 (1.24–2.59) 0.002
Multivariate 9 1592 1.4 0.422 1.75 (1.37–2.22) < 0.001
Sample size       
> 150 8 1703 18.8 0.281 1.33 (1.10–1.61) 0.003
≤150 10 984 0 0.494 1.97 (1.51–2.56) < 0.001
Cancer subtype       
IDC 6 934 43.3 0.116 1.37 (1.11–1.68) 0.003
TNBC 4 590 0 0.933 1.88 (1.39–2.55) < 0.001
RFS Overall 5 1292 79.7 0.001 1.53 (0.73–3.18) 0.259
  1. OS overall survival, DFS disease-free survival, RFS recurrence-free survival, IHC immunohistochemistry, IDC infiltrating ductal carcinoma, TNBC triple-negative breast cancer, SI staining index, HR hazard ratio